Results 51 to 60 of about 42,354 (173)

Lymphocyte subsets in untreated thalassemia patients: differences by genotype and age

Frontiers in Immunology
BackgroundThe Lymphocyte subsets in treatment-naïve patients and their variations among different genetic subtypes and age groups remain poorly characterized.MethodsTo characterize the distribution of lymphocyte subsets in treatment-naïve thalassemia ...
Renbin Zhao, Renbin Zhao, Renbin Zhao, Xiangmei Yao, Xiangmei Yao, Xiangmei Yao, Shuai Feng, Shuai Feng, Shuai Feng, Peng Hu, Yunlian Zou, Yunlian Zou, Yunlian Zou, Zefeng Yang, Zefeng Yang, Zefeng Yang, Jinping Zhang, Jinping Zhang, Jinping Zhang, Xin Guan, Xin Guan, Xin Guan, Chaoran Zhang, Chaoran Zhang, Chaoran Zhang, Zhongyu Wang, Jie Zhang, Zengzheng Li, Zengzheng Li, Zengzheng Li, Yajie Wang, Yajie Wang, Yajie Wang   +32 more
doaj   +1 more source

Differential expression and clinical significance of miR-124-3p in β-thalassemia [PDF]

Jichu yixue yu linchuang
Objective To investigate the differential expression of miR-124-3p in peripheral blood and clinical significance of patients with β-thalassemia. Methods Peripheral blood samples were collected from 33 patients with β-thalassemia and 30 healthy controls
CAO Luoyuan, DONG Wenxu, YANG Jing, GUO Liwen, LU Jiaojiao, ZHENG Xian, FU Xianguo
doaj   +1 more source

Correction of Ineffective Erythropoiesis and Normalization of Iron Homeostasis After Exagamglogene Autotemcel in Transfusion‐Dependent β‐Thalassemia

American Journal of Hematology, EarlyView.
ABSTRACT Exagamglogene autotemcel (exa‐cel) is a one‐time, ex vivo, CRISPR‐Cas9 gene edited cell therapy approved for patients with transfusion dependent β‐thalassemia (TDT) aged 12–35 years. In a Phase 3 study (CLIMB THAL‐111), exa‐cel treatment resulted in reactivation of fetal hemoglobin and increases in total hemoglobin, leading to transfusion ...
Sujit Sheth, Selim Corbacioglu, Josu de la Fuente, Mattia Algeri, Joachim Rupprecht, Kevin H. M. Kuo, Ami J. Shah, Peter Lang, Hayley Merkeley, Ben Carpenter, Markus Y. Mapara, Robert I. Liem, Stephan Grupp, Yogi Chopra, Amanda M. Li, Janet L. Kwiatkowski, Melanie Kirby‐Allen, Maria Domenica Cappellini, Antonis Kattamis, Sakellarios Zairis, Tina Liu, William Hobbs, Haydar Frangoul, Franco Locatelli, Roland Meisel, on behalf of the CLIMB THAL‐111 and CLIMB‐131 Study Groups   +25 more
wiley   +1 more source

Cellular and biochemical heterogeneity contributes to the phenotypic diversity of transfusion-dependent β-thalassemia

Blood Advances
Abstract Transfusion-dependent thalassemia (TDT) is a type of protein aggregation disease. Its clinical heterogeneity imposes challenges in effective management. Red blood cell (RBC) variables may be clinically relevant as mechanistic parts or tellers of TDT pathophysiology.
Konstantina Theocharaki, Alkmini T. Anastasiadi, Sophia Delicou, Vassilis L. Tzounakas, Ioanna Barla, Stella Rouvela, Evgenia Kazolia, Georgia Tzafa, George Mpekoulis, Theodore Gousdovas, Efthymia Pavlou, Ioannis V. Kostopoulos, Athanassios D. Velentzas, Nikolaos Simantiris, Aikaterini Xydaki, Niki Vassilaki, Ersi Voskaridou, Ioanna-Katerina Aggeli, Efrosyni Nomikou, Ourania Tsitsilonis, Efstathia Papageorgiou, Nikolaos Thomaidis, Evangelos Gikas, Marianna Politou, Veroniki Komninaka, Marianna H. Antonelou   +25 more
openaire   +3 more sources

Therapeutic Silencing of Tmprss6 Reduces Iron‐Induced Inflammation and Prolongs Survival in MDS Mice

American Journal of Hematology, EarlyView.
ABSTRACT Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic disorders characterized by ineffective hematopoiesis, cytopenias, and an increased risk of progression to acute myeloid leukemia (AML). Despite advances in supportive and targeted therapies, disease‐modifying interventions remain limited.
Shahla Vilcassim, Nuttanan Pholngam, Rattanawan Thubthed, Tiwaporn Nualkaew, Saovaros Svasti, Pornthip Chaichompoo, Kai Kysenius, Peter J. Crouch, Sibylle Dames, Mona Eisermann, Alberto Martinez, Ute Schaeper, Jim Vadolas, George Grigoriadis   +13 more
wiley   +1 more source

Deletional a-thalassemia 1 gene detection and hematological analysis in carrier with β-thalassemia

Journal of Associated Medical Sciences, 2012
There are high prevalence of β-thalassemia and α-thalassemia in the upper Northern Thailand. Thus, the interaction between β-thalassemia and α-thalassemia can be occurred.
Sitthichai Panyasai
doaj  

Relationship between Ferritin Levels with Calcium Levels in Patients Thalassemia β Major in Hospital in Jember

Journal of Agromedicine and Medical Sciences (AMS), 2023
Thalassemia β major is a hereditary disorder caused by mutations in the β-globin gene, which regulates the formation of one of the components that make up hemoglobin. This disorder results in the production of β-globin chains being reduced or not formed.
Fantya Cerebella Aslamy, Rini Riyanti, Cholis Abrori   +2 more
doaj   +1 more source

Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study

Haematologica, 2019
β-thalassemia, a hereditary blood disorder caused by defective synthesis of hemoglobin β globin chains, leads to ineffective erythropoiesis and chronic anemia that may require blood transfusions.
Maria Domenica Cappellini, John Porter, Raffaella Origa, Gian Luca Forni, Ersi Voskaridou, Frédéric Galactéros, Ali T. Taher, Jean-Benoît Arlet, Jean-Antoine Ribeil, Maciej Garbowski, Giovanna Graziadei, Chantal Brouzes, Michaela Semeraro, Abderrahmane Laadem, Dimana Miteva, Jun Zou, Victoria Sung, Tatiana Zinger, Kenneth M. Attie, Olivier Hermine   +19 more
doaj   +1 more source

Expanding the Utility of Exome Sequencing in Preventive and Population Genetics

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT Carrier screening is a long‐standing genetic testing process offered to at‐risk couples, with or without a family history, who might have pregnancies affected by an autosomal recessive (AR) or X‐linked (XL) disorder. A total of 276 unrelated individuals, initially referred for rare disorder screening by clinicians, were enrolled in this study ...
Charilaos Kostoulas, Athanasia Sesse, Ioanna Bouba, Robert Najdecki, Spyridon Konitsiotis, Sofia Markoula, Ioannis Georgiou   +6 more
wiley   +1 more source

Efficacy and safety of hydroxyurea therapy on patients with β-thalassemia: a systematic review and meta-analysis

Frontiers in Medicine
ObjectiveOur aim is to review the safety and efficacy of hydroxyurea (HU) on β-thalassemia patients.MethodsStudies that evaluated the safety and efficacy of HU on β-thalassemia patients were searched in Pub-Med, Cochrane Databases, Web of Science, China ...
Tianmin Huang, Huixian Jiang, Ganling Tang, Jingyi Li, Xiaoman Huang, Zhenguang Huang, Hongliang Zhang   +6 more
doaj   +1 more source